Published in Genetics and Environmental Health Week, January 12th, 2005
Allergy Therapeutics believes a sublingual allergy vaccine has significant potential to capture market share from symptomatic treatments, such as antihistamines, as it could be self-administered at home and prescribed by general practitioners. Allergy Therapeutics is developing a sublingual vaccine incorporating MPL, which is at the proof of concept stage, the outcome of which is expected in the first half of 2005.
The patent is very...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Health Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.